EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Preventive Intake of a Multiple Micronutrient Supplement during Mild, Acute SARS-CoV-2 Infection to Reduce the Post-Acute COVID-19 Condition: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Teresa Maria Tomasa-Irriguible iD, Ramon Monfà iD, Cristina Miranda-Jiménez, Rosa Morros, Neus Robert, Luisa Bordejé-Laguna, Sandra Vidal, Pere Torán-Monserrat iD, Ana Maria Barriocanal iD

Nutrients · 2024

DOI: 10.3390/nu16111631 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Teresa Maria Tomasa-Irriguible und 8 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain. Hauptthemen laut MEDLINE: COVID-19, Dietary Supplements, Micronutrients, SARS-CoV-2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IGTP-HUGTP, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients hospitalized with COVID-19 have low levels of vitamins and trace elements. This could lead to a post-acute COVID-19 condition (PCC) that can worsen a patient’s quality of life. We aimed to study the baseline micronutrient status of patients and assess whether a multiple micronutrient supplement (MMS) taken for 2 weeks at the first sign of COVID-19 symptoms would be able to reduce the incidence of PCC. This double-blind, placebo-controlled, randomized clinical trial was conducted in adult outpatients with acute COVID-19, recruited between 2021 and 2023 in Spain. Of the 285 patients assessed for eligibility, 267 were randomized and 246 were included in the intent-to-treat population. The mean age was 46.8 years, and 68% were female. Overall, 54.6% had micronutrient deficiencies in the acute phase of COVID-19 at baseline, and 26.2% had PCC after 180 days of follow-up (D180). The most frequently recorded PCC symptoms were neurological (14.1%), with 24% patients scoring worse in the cognitive tests compared to their baseline status. The rate of PCC at D180 was similar between the placebo (25.0%) and intervention (27.7%) groups, without significant differences (p = 0.785). Age over 50 years was the most relevant risk factor for developing PCC, followed by female sex. The most important protective factor against PCC was SARS-CoV-2 vaccination. In this population of predominantly middle-aged, white women with acute COVID-19 not requiring hospital admission, MMS intake for 14 days at symptom onset did not prevent PCC nor improve their micronutrient status at D180.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Dietary SupplementsMicronutrientsSARS-CoV-2HumansFemaleMaleDouble-Blind MethodMiddle AgedAdultSpainPost-Acute COVID-19 SyndromeAged

Stichwörter der Autor:innen

COVID-19SARS-CoV-2cognitive assessmentcognitive impairmentlong COVIDmicronutrientsmultiple micronutrient supplementnutritional statuspost-COVID-19 conditionquality of life

Substanzen

Micronutrients

Autor:innen und Institutionen

  • Intensive Care Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.
  • Jordi Gol University Research Institute in Primary Care (IDIAP Jordi Gol), 08007 Barcelona, Spain.
  • Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona (UAB), 08193 Bellaterra, Spain.
  • Emergency Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.
  • Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain.
  • North Metropolitan Research Support Unit, Jordi Gol University Research Institute in Primary Care (NM-IDIAP Jordi Gol), 08303 Mataró, Spain.

ORCID-Profile: Teresa Maria Tomasa-Irriguible, Ramon Monfà, Pere Torán-Monserrat, Ana Maria Barriocanal

Förderung

  • IGTP-HUGTP
  • Bayer

Zitieren

APA

Tomasa-Irriguible, T. M., Monfà, R., Miranda-Jiménez, C., Morros, R., Robert, N., Bordejé-Laguna, L., Vidal, S., Torán-Monserrat, P., & Barriocanal, A. M. (2024). Preventive Intake of a Multiple Micronutrient Supplement during Mild, Acute SARS-CoV-2 Infection to Reduce the Post-Acute COVID-19 Condition: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Nutrients. https://doi.org/10.3390/nu16111631

Vancouver

Tomasa-Irriguible TM, Monfà R, Miranda-Jiménez C, Morros R, Robert N, Bordejé-Laguna L, et al. Preventive Intake of a Multiple Micronutrient Supplement during Mild, Acute SARS-CoV-2 Infection to Reduce the Post-Acute COVID-19 Condition: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Nutrients. 2024. doi:10.3390/nu16111631

BibTeX
@article{TomasaIrriguible2024,
  author = {Tomasa-Irriguible, Teresa Maria and Monfà, Ramon and Miranda-Jiménez, Cristina and Morros, Rosa and Robert, Neus and Bordejé-Laguna, Luisa and Vidal, Sandra and Torán-Monserrat, Pere and Barriocanal, Ana Maria},
  title = {Preventive Intake of a Multiple Micronutrient Supplement during Mild, Acute SARS-CoV-2 Infection to Reduce the Post-Acute COVID-19 Condition: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16111631}
}
Kostenlos starten →